Data gathered: April 4
AI Stock Analysis - Geron (GERN)
Analysis generated October 29, 2024. Powered by Chat GPT.
Geron Corporation is a biotechnology company focused on the development and commercialization of innovative therapeutic treatments. The company's primary product candidate, imetelstat, is a first-in-class telomerase inhibitor in various stages of clinical trials for hematologic myeloid malignancies. Geron has established a robust pipeline and strategic collaborations that strengthen its prospects in a competitive market. Despite facing numerous challenges and fluctuations in its financial performance, Geron's focus on pioneering treatments places it in a unique position within the healthcare sector.
Stock Alerts - Geron (GERN)
 |
Geron | April 3 Price is down by -5% in the last 24h. |
|
Geron | April 2 Price is up by 5.1% in the last 24h. |
|
Geron | April 1 Price is down by -6% in the last 24h. |
|
Geron | March 31 Price is down by -5.5% in the last 24h. |
Alternative Data for Geron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 20,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 59 | Sign up | Sign up | Sign up |
| Patents | 30 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 74 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 21,282 | Sign up | Sign up | Sign up |
| Twitter Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 49 | Sign up | Sign up | Sign up |
| Linkedin Employees | 381 | Sign up | Sign up | Sign up |
About Geron
Geron Corporation is a biotechnology company located in Foster City, California, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
| Price | $1.47 |
| Target Price | Sign up |
| Volume | 10,400,000 |
| Market Cap | $1.01B |
| Year Range | $1.47 - $4.78 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Earnings Date | May 7 '25 |
| Industry | Biotechnology |
In the news
GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your RightsApril 3 - Finnhub |
|
Investors in Geron Corporation Should Contact The Gross Law Firm Before May 12, 2025 to Discuss Your Rights – GERNApril 3 - GlobeNewswire |
|
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law FirmApril 3 - Finnhub |
|
GERN Investors Have Opportunity to Lead Geron Securities Fraud Lawsuit with Faruqi & Faruqi, LLPApril 3 - Finnhub |
|
GERN INVESTOR ALERT: Kirby McInerney LLP Notifies Geron Corporation Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitApril 2 - GlobeNewswire |
|
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GeronApril 2 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 28M | 36M | -7.6M | -26M | -28M | -0.040 |
| Q2 '24 | 880,000 | 39M | -39M | -67M | -69M | -0.100 |
| Q1 '24 | 300,000 | 27M | -30M | -55M | -56M | -0.090 |
| Q4 '23 | 23,000 | 22M | -24M | -52M | -54M | -0.090 |
| Q3 '23 | 160,000 | 18M | -20M | -45M | -48M | -0.080 |
Insider Transactions View All
| SCARLETT JOHN A filed to buy 12,500 shares at $1.8. March 3 '25 |
| Samuels Scott Alan filed to buy 26,682 shares at $1.6. March 3 '25 |
| Ziegler James filed to buy 100,000 shares at $1.6. March 3 '25 |
Similar companies
Read more about Geron (GERN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Geron?
The Market Cap of Geron is $1.01B.
When does Geron report earnings?
Geron will report its next earnings on May 7 '25.
What is the current stock price of Geron?
Currently, the price of one share of Geron stock is $1.47.
How can I analyze the GERN stock price chart for investment decisions?
The GERN stock price chart above provides a comprehensive visual representation of Geron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Geron shares. Our platform offers an up-to-date GERN stock price chart, along with technical data analysis and alternative data insights.
Does GERN offer dividends to its shareholders?
As of our latest update, Geron (GERN) does not offer dividends to its shareholders. Investors interested in Geron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Geron?
Some of the similar stocks of Geron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.